Old Web
English
Sign In
Acemap
>
authorDetail
>
Haidong Wang
Haidong Wang
Southwest General Health Center
Placebo
Metformin
Epidermal growth factor receptor
Oncology
Gefitinib
2
Papers
19
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Combination of metformin and gefitinib as first-line therapy for non-diabetic advanced NSCLC patients with EGFR mutations: A randomized, double-blind phase 2 trial
2019
Clinical Cancer Research
Li Li
Liyan Jiang
Yubo Wang
Yizhuo Zhao
Xiaoju Zhang
Guoming Wu
Xiangdong Zhou
Jianguo Sun
Jun Bai
Biyong Ren
Kun Tian
Zhi Xu
Hualiang Xiao
Qi Zhou
Rui Han
Hengyi Chen
Haidong Wang
Zhenzhou Yang
Chan Gao
Shangli Cai
Yong He
Show All
Source
Cite
Save
Citations (18)
Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
2019
Journal of Clinical Oncology
Yong He
Li Li
Liyan Jiang
Yubo Wang
Yizhuo Zhao
Xiaoju Zhang
Guoming Wu
Xiangdong Zhou
Jianguo Sun
Jun Bai
Biyong Ren
Kun Tian
Zhi Xu
Hualiang Xiao
Qi Zhou
Rui Han
Hengyi Chen
Haidong Wang
Zhenzhou Yang
Chan Gao
Show All
Source
Cite
Save
Citations (1)
1